MRI and PET in Hematology and Oncology
This special issue belongs to |
Research & Reviews : Journal of Medical Science and Technology |
Related section |
NA |
Deadline for Manuscript Submission |
March 31st, 2023 |
Deadline for Publication |
April 15, 2023 |
Special Issue Description
Dear Collegues,
Planning effective cancer therapy requires accurate staging and precise measurement of tumor burden. It is equally important to evaluate therapeutic changes when changing the therapeutic approach. As it has proven to be more sensitive than contrast-enhanced CT in the staging of lymphoma and the diagnosis of diffuse neoplasms, FDG-PET/CT has become a cornerstone in the diagnosis and restaging of neoplasms, in the assessment of therapeutic efficacy during or after treatment, and the planning of radiotherapy. Due to the lack of ionizing radiation, the high soft tissue contrast, and the good spatial resolution of MRI, it has only recently been accepted as an alternate approach for the diagnosis and staging of different hematologic and oncologic illnesses, particularly in younger patients. However, the diagnostic efficacy of MRI in oncology has been further enhanced by the use of sophisticated sequences, such as DWI.
The diagnostic efficacy of MRI in onco -hematological imaging has been greatly improved by the recently established whole body (WB) MRI technology, offering outstanding complete body imaging. Only WB-MRI for myeloma is now acknowledged as a very sensitive diagnostic for diagnosis and staging. In lymphoma, WB-DWI-MRI merely acts as a substitute for FDG-PET/CT, particularly in juvenile patients, while its application in adult patients is becoming more significant. WB DWI MRI is not yet recommended in current guidelines, despite its great sensitivity in the diagnosis and follow-up of lymphomas and non-hematologic malignancies. A relatively young hybrid imaging technology, PET/MRI, has just entered common clinical practice.
Recent comparison investigations comparing hybrid PET/CT and PET/MRI imaging modalities in limited patient populations have yielded promising early findings that favor MRI.
Keywords
*MRI *Whole Body MRI *Diffusion-Weighted Imaging *PET/MRI *Hematology *Oncology *Lymphoma *Myeloma *Radiopharmaceuticals *CNS tumor *Head & neck tumor *Liver cancer *Gynecological cancer *Musculoskeletal tumor
Manuscript Submission information
Manuscripts should be submitted online by registering and logging in to this link. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed.
Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent on email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.